AAA

Affinity Asset Advisors Portfolio holdings

AUM $676M
1-Year Est. Return 29.75%
This Quarter Est. Return
1 Year Est. Return
+29.75%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$639M
AUM Growth
-$1.35M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
109
New
Increased
Reduced
Closed

Top Buys

1
+$16.8M
2
+$15.6M
3
+$13.1M
4
NUVL icon
Nuvalent
NUVL
+$12.4M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$11.9M

Top Sells

1
+$12.1M
2
+$10.3M
3
+$5.72M
4
ARWR icon
Arrowhead Research
ARWR
+$5.64M
5
SYRE icon
Spyre Therapeutics
SYRE
+$5.53M

Sector Composition

1 Healthcare 90.82%
2 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTTB icon
76
Q32 Bio
QTTB
$27.6M
$45.8K ﹤0.01%
27,777
RCKTW icon
77
Rocket Pharmaceuticals Warrant
RCKTW
$3.2M
$3.52K ﹤0.01%
75,000
IMTXW
78
DELISTED
Immatics N.V. Warrants
IMTXW
$2.96K ﹤0.01%
187,204
ALNY icon
79
Alnylam Pharmaceuticals
ALNY
$58.5B
– –
0
AMGN icon
80
Amgen
AMGN
$172B
– –
0
APLS icon
81
Apellis Pharmaceuticals
APLS
$2.44B
– –
-50,000
ARVN icon
82
Arvinas
ARVN
$753M
– –
-630,000
ARWR icon
83
Arrowhead Research
ARWR
$5.42B
– –
-300,000
BMEA icon
84
Biomea Fusion
BMEA
$96.9M
– –
0
CGON icon
85
CG Oncology
CGON
$3.03B
– –
-100,000
CLDX icon
86
Celldex Therapeutics
CLDX
$1.52B
– –
-9,992
CMPS
87
Compass Pathways
CMPS
$523M
– –
-850,512
CORT icon
88
Corcept Therapeutics
CORT
$7.75B
– –
0
EWTX icon
89
Edgewise Therapeutics
EWTX
$1.82B
– –
0
EXEL icon
90
Exelixis
EXEL
$10.9B
– –
0
GALT icon
91
Galectin Therapeutics
GALT
$335M
– –
0
IBRX icon
92
ImmunityBio
IBRX
$2.1B
– –
0
IWM icon
93
iShares Russell 2000 ETF
IWM
$69.3B
– –
0
KZR icon
94
Kezar Life Sciences
KZR
$44.2M
– –
-142,316
MESO
95
Mesoblast
MESO
$1.87B
– –
0
NMRA icon
96
Neumora Therapeutics
NMRA
$428M
– –
0
RAPT icon
97
RAPT Therapeutics
RAPT
$800M
– –
-125,000
SAVA icon
98
Cassava Sciences
SAVA
$143M
– –
0
SVRA icon
99
Savara
SVRA
$795M
– –
-410,586
TRML
100
DELISTED
Tourmaline Bio
TRML
– –
0
1 2 3
4
5